Lactoferrin/LTF Protein, Human (691a.a, HEK293, His)
Based on 1 Customer Validation
Lactoferrin (LTF) is a major iron-binding protein in exocrine fluid and exhibits multiple antibacterial effects by chelating iron and disrupting bacterial membranes. It prevents biofilm formation, affects bone metabolism, and affects adenovirus and papillomavirus infections. Lactoferrin/LTF Protein, Human (691a.a, HEK293, His) is the recombinant human-derived Lactoferrin/LTF protein, expressed by HEK293 , with C-6*His labeled tag.
- Species: Human
- Source: HEK293
-
Storage:Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Biological Activity
Description
Lactoferrin (LTF) is a major iron-binding protein in exocrine fluid and exhibits multiple antibacterial effects by chelating iron and disrupting bacterial membranes. It prevents biofilm formation, affects bone metabolism, and affects adenovirus and papillomavirus infections. Lactoferrin/LTF Protein, Human (691a.a, HEK293, His) is the recombinant human-derived Lactoferrin/LTF protein, expressed by HEK293 , with C-6*His labeled tag.
Background
Lactoferrin (LTF), a major iron-binding and multifunctional protein present in exocrine fluids such as breast milk and mucosal secretions, exhibits diverse biological activities. Renowned for its antimicrobial properties, LTF hinders microbial growth through sequestering free iron and releasing lipopolysaccharides from the bacterial outer membrane, thereby displaying both bacteriostatic and bactericidal effects. Moreover, it plays a role in preventing bacterial biofilm development in Pseudomonas aeruginosa infections and demonstrates weak antifungal activity against Candida albicans. Beyond its antimicrobial functions, LTF impacts bone metabolism by exerting anabolic, differentiating, and anti-apoptotic effects on osteoblasts, while also inhibiting osteoclastogenesis. It contributes to adenovirus infection by promoting the binding of species C adenoviruses to epithelial cells and inhibits papillomavirus infections. LTF stimulates the TLR4 signaling pathway, leading to NF-kappa-B activation and pro-inflammatory cytokine production, while concurrently interfering with lipopolysaccharide-stimulated TLR4 signaling. Additionally, it exhibits inhibitory effects on neutrophil granulocyte migration and promotes VEGFA-mediated endothelial cell migration and proliferation. LTF's versatility extends to its binding capabilities, encompassing interactions with heparin, chondroitin sulfate, pneumococcal surface protein A, lysozyme, and DNA.
MCE Validation Data
-
Purity - SDS-PAGE
Purity - SDS-PAGE
Technical Parameters
-
Species Human
-
Source HEK293
-
Tag C-6*His
-
Accession
AAH15822.1 (G20-K711)
-
Molecular Construction
-
N-term
-
LTF (G20-K711)
Accession # AAH15822.1 -
6*His
-
C-term
-
-
Protein Length
Partial
-
Synonyms
LTF; Epididymis Luminal Protein 110; Lactotransferrin; Neutrophil Lactoferrin; HLF2; Lactoferricin; Growth-Inhibiting Protein 12; Lactoferroxin; Talalactoferrin; Lactoferrin; GIG12; Kaliocin-1; LF; HEL110
-
AA Sequence
GSRRRSVQWCAVSQPEATKCFQWQRNMRKVRGPPVSCIKRDSPIQCIQAIAENRADAVTLDGGFIYEAGLAPYKLRPVAAEVYGTERQPRTHYYAVAVVKKGGSFQLNELQGLKSCHTGLRRTAGWNVPIGTLRPFLNWTGPPEPIEAAVARFFSASCVPGADKGQFPNLCRLCAGTGENKCAFSSQEPYFSYSGAFKCLRDGAGDVAFIRESTVFEDLSDEAERDEYELLCPDNTRKPVDKFKDCHLARVPSHAVVARSVNGKEDAIWNLLRQAQEKFGKDKSPKFQLFGSPSGQKDLLFKDSAIGFSRVPPRIDSGLYLGSGYFTAIQNLRKSEEEVAARRARVVWCAVGEQELRKCNQWSGLSEGSVTCSSASTTEDCIALVLKGEADAMSLDGGYVYTAGKCGLVPVLAENYKSQQSSDPDPNCVDRPVEGYLTVAVVRRSDTSLTWNSVKGKKSCHTAVDRTAGWNIPMGLLFNQTGSCKFDEYFSQSCAPGSDPRSNLCALCIGDEQGENKCEPNSNERYYGYTGAFRCLAENAGDVAFVKDVTVLQNTDGNNNEAWAKDLKLADFALLCLDGKRKPVTEARSCHLAMAPNHAVVSRMDKVERLKQVLLHQQAKFGRNGSDCPDKFCLFQSETKNLLFNDNTECLARLHGKTTYEKYLGPQYVAGITNLKKCSTSPLLEACEFLRK
-
Predicted Molecular Mass
77.3 kDa
-
Molecular Weight
Approximately 90 kDa, based on SDS-PAGE under reducing conditions.
-
Glycosylation
Yes
-
Purity
≥ 95%, as determined by reducing SDS-PAGE.
Product Properties
Lyophilized powder.
Lyophilized from a 0.22 μm filtered solution of 20 mM PB, 150 mM NaCl, pH 7.4.
<1 EU/μg, determined by LAL method.
It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH2O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).
Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Room temperature in continental US; may vary elsewhere.
Documentation
-
Data Sheet (240 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)